BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.
To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.
To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.
(Reuters) — Teva Pharmaceutical Industries will pay up to $523 million to New York State as part of a nationwide settlement of lawsuits alleging it helped to fuel the U.S. opioid epidemic.
CEO Kare Schultz said Israel-based Teva, the world's largest generic drugmaker, will make the payment over 18 years, “which is good for us because it means that it's very manageable in relation to our cash flow and our debt situation.”
“We are quite satisfied with that outcome,” Mr. Schultz told an analysts call after Teva reported third-quarter results that missed expectations and sent its Tel Aviv shares down more than 6%.
After years of negotiations, Teva in July proposed a $4.25 billion nationwide settlement — mostly cash and partly medicines that will amount to $300 million to $400 million over 13 years — to resolve opioid lawsuits.
It expects to start paying in 2023, but it is still in the process of convincing states and counties to accept its proposal.
“We are quite optimistic that we will get a very, very high number of states and subdivisions joining, and we will put the majority of opioid litigation behind us,” Mr. Schultz said.
On Tuesday, CVS Health Corp., Walgreens Boots Alliance and Walmart agreed to pay $13.8 billion to resolve thousands of U.S. state and local lawsuits related to opioid pain drugs.